ABVC Biopharma Inc.
06/04/2025 | Press release | Distributed by Public on 06/04/2025 14:02
Proxy Results (Form 8-K)
Item 5.07 Submission of Matters to a Vote of Security Holders.
On June 3, 2025, ABVC BioPharma, Inc. (the "Company") held its 2025 annual meeting of shareholders (the "Annual Meeting"). At the Annual Meeting, the Company's shareholders voted on 4 proposals. At the beginning of the Annual Meeting, 5,917,309 shares of common stock, which represents 35.27% of the voting power of the shares entitled to vote at the Annual Meeting, were represented by proxy, which constituted a quorum for the transaction of business.
We are filing this Current Report on Form 8-K to disclose the voting results from the Annual Meeting.
| 1. | To re-elect 11 directors to the Company's board of directors (the "Board"), with such directors to serve until the 2025 annual meeting of shareholders. |
| Name | For | Against | Withheld | |||||||||
| Eugene Jiang | 5,898,784 | 0 | 18,525 | |||||||||
| Dr. Tsang Ming Jiang | 5,898,784 | 0 | 18,525 | |||||||||
| Norimi Sakamoto | 5,898,784 | 0 | 18,525 | |||||||||
| Yen-Hsin Chou | 5,898,784 | 0 | 18,525 | |||||||||
| Dr. Tsung-Shann (T.S.) Jiang | 5,898,784 | 0 | 18,525 | |||||||||
| Dr. Chang-Jen Jiang | 5,898,784 | 0 | 18,525 | |||||||||
| Hsin-Hui Miao | 5,898,784 | 0 | 18,525 | |||||||||
| Yoshinobu Odaira | 5,898,784 | 0 | 18,525 | |||||||||
| Che-Wei Hsu | 5,898,784 | 0 | 18,525 | |||||||||
| Shuling Jiang | 5,898,784 | 0 | 18,525 | |||||||||
| Yu-Min (Francis) Chung | 5,898,784 | 0 | 18,525 | |||||||||
Accordingly, all directors were re-elected.
| 2. | To ratify the appointment of Simon & Edward, LLP as the Company's independent registered public accounting firm for fiscal year ending December 31, 2025. |
| For | Against | Abstain | ||
| 5,903,606 | 10,152 | 3,551 |
Accordingly, Simon & Edward, LLP was reappointed as the Company's independent registered public accounting firm for fiscal year ending December 31, 2025.
| 3. | To authorize, for purposes of complying with Nasdaq Listing Rule 5635(b) and Nasdaq Listing Rule 5635(d), the entry into an agreement to purchase land owned by one of our directors, Shuling Jiang ("Shuling") and to purchase such land via the issuance of shares of our common stock and warrants to purchase shares of common stock, which constitutes a related party transaction and which may result in the issuance of an amount of shares of common stock equal to or in excess of 20% of our common stock outstanding and which Nasdaq may deem a "change of control" transaction (the "Land Proposal"). |
| For | Against | Abstain | ||
| 5,832,130 | 81,700 | 3,479 |
Accordingly, the Land Proposal was approved.
| 4. | To approve an increase in the Company's Amended and Restated 2016 Equity Incentive Plan (the "Plan") up to a maximum of 15% of the number of issued and outstanding shares on the date of the Meeting and permit the automatic increase of such shares available under the Plan, on January 1 of each year, by that number of shares equal to 5% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, commencing on January 1, 2026 and ending with the year that the additional number of shares equals 15% of the number of shares of common stock issued and outstanding as of December 31 of the previous year (the "Plan Proposal"). |
| For | Against | Abstain | ||
| 5,691,168 | 222,663 | 3,478 |
Accordingly, the Plan Proposal was approved.
ABVC Biopharma Inc. published this content on June 04, 2025, and is solely responsible for the information contained herein. Distributed via SEC EDGAR on June 04, 2025 at 20:02 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]